An independent two-stage DCF analysis by a frontier AI model.
"> Abbott is a diversified healthcare leader. While COVID testing revenues have evaporated, its medical devices (like FreeStyle Libre) continue to grow impressively. An 8% FCF growth assumption models stable, low-double-digit medical device growth blended with mature pharma and nutritional segments.
"> Abbott is a diversified healthcare leader. While COVID testing revenues have evaporated, its medical devices (like FreeStyle Libre) continue to grow impressively. An 8% FCF growth assumption models stable, low-double-digit medical device growth blended with mature pharma and nutritional segments.
"> Abbott is a diversified healthcare leader. While COVID testing revenues have evaporated, its medical devices (like FreeStyle Libre) continue to grow impressively. An 8% FCF growth assumption models stable, low-double-digit medical device growth blended with mature pharma and nutritional segments.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 7.5% | 8.0% | 8.5% | 9.0% | 9.5% |
|---|---|---|---|---|---|
| 7.5% | $44.30 | $44.30 | $44.30 | $44.30 | $44.30 |
| 8.0% | $44.30 | $44.30 | $44.30 | $44.30 | $44.30 |
| 8.5% | $44.30 | $44.30 | $44.30 | $44.30 | $44.30 |
| 9.0% | $44.30 | $44.30 | $44.30 | $44.30 | $44.30 |
| 9.5% | $44.30 | $44.30 | $44.30 | $44.30 | $44.30 |
■ Undervalued vs current price ■ Overvalued vs current price
Diversified medtech/diagnostics company. FreeStyle Libre CGM is the growth star. Post-COVID diagnostics revenue normalization creates tough comps.
Westmount Research. "Abbott Laboratories (ABT) Intrinsic Value: A DCF Analysis." westmountfundamentals.com, March 18, 2026.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.